KLRAKailera Therapeutics, Inc.

Healthcare
$11.61

The financials

Kailera Therapeutics, Inc. by the numbers

The next results filing is expected around Nov 11, 2026, a quarter after the last one.

Kailera Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$121M−$20Mn/a
Net income−$111M−$18Mn/a
Diluted EPS−$1.09−$17983.00n/a

Biotechnology

The closest names by size in the same industry

Compare peers
CLDX+2.1%
Celldex Therapeutics, Inc.
IRON+2.2%
Disc Medicine, Inc.
TARS+1.2%
Tarsus Pharmaceuticals, Inc.
TRVI+3.0%
Trevi Therapeutics, Inc.
RARE+1.4%
Ultragenyx Pharmaceutical Inc.
VERA+0.44%
Vera Therapeutics, Inc.